Veru Inc Zukünftige P/E
Was ist das Zukünftige P/E von Veru Inc?
Zukünftige P/E von Veru Inc ist -0.88
Was ist die Definition von Zukünftige P/E?
Das Terminkurs-Gewinn-Verhältnis ist das Verhältnis des Aktienkurses eines Unternehmens zum geschätzten Gewinn des Unternehmens für die nächsten zwölf Monate.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Zukünftige P/E von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Veru Inc
Was macht Veru Inc?
the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries
Unternehmen mit zukünftige p/e ähnlich Veru Inc
- GEN III Oil hat Zukünftige P/E von -0.91
- Top Ships Inc hat Zukünftige P/E von -0.91
- Diffusion Pharmaceuticals Inc hat Zukünftige P/E von -0.90
- Viking hat Zukünftige P/E von -0.90
- Sangamo Therapeutics Inc hat Zukünftige P/E von -0.90
- Sol-Gel Technologies Ltd hat Zukünftige P/E von -0.90
- Veru Inc hat Zukünftige P/E von -0.88
- Thin Film Electronics ASA hat Zukünftige P/E von -0.87
- Enertime SA hat Zukünftige P/E von -0.86
- Minerva Neurosciences Inc hat Zukünftige P/E von -0.85
- Centogene NV hat Zukünftige P/E von -0.85
- Check-Cap Ltd hat Zukünftige P/E von -0.84
- Bonavista hat Zukünftige P/E von -0.83